Reducing Unused Prescribed Opioids After Cesarean Birth

减少剖腹产后未使用的处方阿片类药物

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Over the past 15 years, the United States has seen the emergence of an opioid epidemic with drug overdose ranking as the most common cause for accidental death. The rise in drug overdose deaths mirrors the rise in legal opioid prescribing. Unfortunately, most persons using opioids for non-medical purposes obtain them from a family member or friend who was legitimately prescribed opioids. While significant attention has been devoted to prescribing recommendations for individuals with chronic pain and for acute post-surgical pain, much less attention has been given to post-surgical opioid prescribing after hospital discharge. As the most common abdominal surgery in the United States, cesarean birth is the ideal setting to examine methods to reduce unused prescribed opioids. My preliminary work demonstrates that most women have unused opioids after cesarean birth, however a significant proportion of women use all opioids and have unmet pain needs. In addition, current opioid prescribing practices appear to be largely based on prescriber habits rather than patient need. This body of work endeavors to 1) characterize post-discharge opioid use patterns and identify demographic and obstetric variables associated with differential use 2) create and validate a clinical decision support tool that predicts customized post-discharge opioid need and 3) conduct a pilot randomized clinical trial comparing prescribing guided by the CDS tool to standard care to test whether this tool reduces unused opioids without increasing unmet pain after cesarean birth. The overarching objective of this mentored career development experience is to emerge as an independent clinical investigator leading a multidisciplinary research program to improve opioid prescribing after hospital discharge. To accomplish this goal, I will augment my prior research training with advanced coursework and skills development in predictive modeling and conducting clinical trials as well as leadership training focused on opioid prescribing and maternal and infant public health systems. Throughout the award period, the I will work closely with a multidisciplinary team of mentors and advisors—including experts in obstetrics and gynecology, biostatistics, anesthesiology, public health, and epidemiology—to carry out my stated career objectives and specific aims.
项目总结/摘要 在过去的15年里,美国出现了药物过量的阿片类药物流行病 是意外死亡的最常见原因。药物过量死亡人数的增加反映了 法律的阿片类药物处方。不幸的是,大多数使用阿片类药物用于非医疗目的的人从以下来源获得它们: 合法服用阿片类药物的家庭成员或朋友。虽然受到了极大的关注, 致力于为患有慢性疼痛和急性手术后疼痛的个人提供处方建议, 对出院后手术后阿片类药物处方的关注要少得多。作为最 在美国常见的腹部手术中,剖腹产是理想的检查方法, 减少未使用的处方阿片类药物。我的初步研究表明,大多数妇女都有未使用的阿片类药物, 然而,在剖腹产后,很大一部分妇女使用所有阿片类药物,疼痛需求未得到满足。在 此外,目前的阿片类药物处方实践似乎主要基于处方者的习惯,而不是 病人的需要。这项工作的主体努力1)表征出院后阿片类药物使用模式,并确定 与差异使用相关的人口统计学和产科变量2)创建并验证临床决策 预测定制出院后阿片类药物需求的支持工具和3)进行试点随机临床试验 将CDS工具指导的处方与标准护理进行比较,以测试该工具是否减少了未使用的 阿片类药物不会增加剖宫产后未满足的疼痛。这个指导职业的首要目标是 发展经验是作为一个独立的临床研究者领导一个多学科 改善出院后阿片类药物处方的研究计划。为了实现这一目标,我将 通过预测建模方面的高级课程和技能开发来增强我之前的研究培训 开展临床试验以及领导力培训,重点是阿片类药物处方和孕产妇和 幼儿公共卫生系统。在整个授予期间,I将与多学科团队密切合作 包括妇产科、生物统计学、麻醉学、公共卫生和社会科学领域的专家, 健康和流行病学-实现我所陈述的职业目标和具体目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah Scheiderich Osmundson其他文献

Sarah Scheiderich Osmundson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sarah Scheiderich Osmundson', 18)}}的其他基金

Comprehensive Postpartum Management for Women with Hypertensive Disorders of Pregnancy
妊娠期高血压疾病妇女的产后综合管理
  • 批准号:
    10708194
  • 财政年份:
    2022
  • 资助金额:
    $ 16.97万
  • 项目类别:
Comprehensive Postpartum Management for Women with Hypertensive Disorders of Pregnancy
妊娠期高血压疾病妇女的产后综合管理
  • 批准号:
    10604847
  • 财政年份:
    2022
  • 资助金额:
    $ 16.97万
  • 项目类别:
Reducing Unused Prescribed Opioids After Cesarean Birth
减少剖腹产后未使用的处方阿片类药物
  • 批准号:
    10224161
  • 财政年份:
    2019
  • 资助金额:
    $ 16.97万
  • 项目类别:
Reducing Unused Prescribed Opioids After Cesarean Birth
减少剖腹产后未使用的处方阿片类药物
  • 批准号:
    10671569
  • 财政年份:
    2019
  • 资助金额:
    $ 16.97万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 16.97万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了